{"Title": "Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine", "Year": 2016, "Source": "Mult. Scler.", "Volume": "22", "Issue": 7, "Art.No": null, "PageStart": 944, "PageEnd": 954, "CitedBy": 15, "DOI": "10.1177/1352458515606809", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84973483351&origin=inward", "Abstract": "\u00a9 SAGE Publications.Background: Multiple sclerosis (MS) is a debilitating disease that negatively impacts patients' lives. Objective: ENABLE assessed the effect of long-term prolonged-release (PR) fampridine (dalfampridine extended release in the United States) treatment on patient-perceived health impact in patients with MS with walking impairment. Methods: ENABLE was a 48-week, open-label, Phase 4 study of PR-fampridine 10 mg twice daily. Patients who showed any improvement in Timed 25-Foot Walk walking speed at weeks 2 and 4 and any improvement in 12-item MS Walking Scale score at week 4 remained on treatment. The primary endpoint was change from baseline in 36-Item Short-Form Health Survey (SF-36) physical component summary (PCS) score. Results: At week 4, 707/901 (78.5%) patients met the criteria to remain on treatment. Patients on treatment demonstrated significant and clinically meaningful improvements in SF-36 PCS scores from baseline (mean change (95% confidence interval)) to week 12 (4.30 (3.83, 4.78); p < 0.0001), week 24 (3.75 (3.23, 4.27); p < 0.0001), week 36 (3.46 (2.95, 3.97); p < 0.0001), and week 48 (3.24 (2.72, 3.77); p < 0.0001). Significant improvements from baseline were also demonstrated in secondary health measures in patients on treatment. Conclusion: PR-fampridine improved patient-perceived physical and psychological health impact of MS measured in a real-life setting.", "AuthorKeywords": ["Fampridine", "multiple sclerosis", "patient-reported outcome", "quality of life"], "IndexKeywords": ["4-Aminopyridine", "Adolescent", "Adult", "Aged", "Australia", "Delayed-Action Preparations", "Disability Evaluation", "Europe", "Exercise Tolerance", "Female", "Gait", "Humans", "Male", "Middle Aged", "Multiple Sclerosis", "Patient Reported Outcome Measures", "Potassium Channel Blockers", "Quality of Life", "Recovery of Function", "Time Factors", "Treatment Outcome", "Walking", "Young Adult"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-84973483351", "SubjectAreas": [["Neurology", "NEUR", "2808"], ["Neurology (clinical)", "MEDI", "2728"]], "AuthorData": {"7005929003": {"Name": "MacDonell R.", "AuthorID": "7005929003", "AffiliationID": "60026553, 60005087", "AffiliationName": "Department of Neurology, Austin Health, University of Melbourne"}, "6603917623": {"Name": "Nagels G.", "AuthorID": "6603917623", "AffiliationID": "60026810, 60070712", "AffiliationName": "National Multiple Sclerosis Center Melsbroek, Center for Neurosciences, Vrije Universiteit Brussel"}, "57217110384": {"Name": "Laplaud D.A.", "AuthorID": "57217110384", "AffiliationID": "60032006, 60073342, 60002895", "AffiliationName": "Centre Hospitalier, Universitaire de Nantes, H\u00f4pital G. et R. Laennec"}, "7005997059": {"Name": "Pozzilli C.", "AuthorID": "7005997059", "AffiliationID": "60032350", "AffiliationName": "Department of Neurology and Psychiatry, Sapienza University"}, "35877256000": {"Name": "De Jong B.", "AuthorID": "35877256000", "AffiliationID": "116770179", "AffiliationName": "Neurology Department of Jeroen Bosch Hospital"}, "8320470900": {"Name": "Martins Da Silva A.", "AuthorID": "8320470900", "AffiliationID": "60000817", "AffiliationName": "Neurosciences Department, Hospital Santo Ant\u00f3nio-Centro Hospitalar Do Porto"}, "15768161200": {"Name": "Nicholas R.", "AuthorID": "15768161200", "AffiliationID": "60015150", "AffiliationName": "Imperial College"}, "6603311349": {"Name": "Lechner-Scott J.", "AuthorID": "6603311349", "AffiliationID": "60089816, 60010571", "AffiliationName": "Hunter Medical Research Institute, University of Newcastle"}, "57189624608": {"Name": "Gaebler J.A.", "AuthorID": "57189624608", "AffiliationID": "60029337", "AffiliationName": "Biogen"}, "36113036400": {"Name": "Agarwal S.", "AuthorID": "36113036400", "AffiliationID": "60029337", "AffiliationName": "Biogen"}, "56497270500": {"Name": "Wang P.", "AuthorID": "56497270500", "AffiliationID": "60029337", "AffiliationName": "Biogen"}, "57189622699": {"Name": "Yeh M.", "AuthorID": "57189622699", "AffiliationID": "60029337", "AffiliationName": "Biogen"}, "57095803100": {"Name": "Hovenden M.", "AuthorID": "57095803100", "AffiliationID": "116312348", "AffiliationName": "Excel Scientific Solutions"}, "55663378300": {"Name": "Soelberg S\u00f8rensen P.", "AuthorID": "55663378300", "AffiliationID": "60006564, 60015199", "AffiliationName": "Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet"}}}